Summary In animals, high fibroblast growth factor 21 (FGF21) states improve insulin resistance but induce bone loss. Whether FGF21 relates to bone mineral density (BMD) is unknown in humans. Contrary to prediction from animal findings, we found higher FGF21 levels associating with greater BMD in women, independent of age and body composition. Introduction Recent laboratory studies suggest that FGF21 is involved in reciprocal regulation of bone and energy homeostasis. Systemic administration of FGF21 protects animals from obesity and diabetes but causes severe bone loss, smothering the enthusiasm over FGF21 as a potential antiobesity therapeutic. To date, there is no information on whether FGF21 relates to BMD in humans. We thus studied the relationship between plasma FGF21 levels and BMD in healthy adults. Methods Fasting plasma FGF21 levels were measured by enzyme-linked immunosorbent assay and body composition by dual-energy X-ray absorptiometry. Results Among 40 healthy volunteers (age 32±10 year, 16 women), men had significantly higher lean body mass (p<0.01) and total BMD (p<0.05), and lower percent body fat than women (p<0.01). Median plasma FGF21 levels were not different between the sexes. While there was no association between FGF21 concentrations and body composition in men, FGF21 levels correlated positively with fat mass (p<0.01) in women. In men, no significant correlation between FGF21 with BMD was observed. However, in women, FGF21 correlated positively with total BMD (R 2 =0.69, p=0.003) and spine BMD (R 2 =0.76, p=0.001); the correlation remained significant after adjusting for age, ethnicity, and body composition. Conclusions This study reveals for the first time a strong positive association between plasma FGF21 levels and BMD in healthy women, suggesting the association between bone loss and high FGF21 states in animals may not be directly translated to humans in physiologic states. We hypothesize that FGF21 may increase bone mass particularly in women through paracrine mechanisms in the bone-adipose interface.
Introduction
Fibroblast growth factor 21 (FGF21) is a newly identified member of the FGF family that plays key roles in energy balance [1] . It is expressed in liver and adipose tissue, acting locally in the regulation of ketogenesis and lipolysis. Aside the autocrine/paracrine action common to most FGFs, FGF21 is also secreted into the circulation, thus functioning as a hormone capable of modulating systemic glucose and lipid metabolism [2] . These properties define FGF21 as a factor with dual endocrine and paracrine actions, orchestrating the interplay between nutrient fluxes and fuel demands.
The effects of FGF21 manipulation in animals with respect to energy balance and bone biology are provocative and dramatic: pharmacological administration of FGF21 imparts profound metabolic benefits, reversing diabetes, hepatic steatosis, and obesity [1, 3, 4] . However, genetic FGF21 over-expression decreases bone mass and systemic FGF21 treatment leads to severe bone loss in mice [5] . Thus FGF21 appears to exert reciprocal regulation of bone and energy homeostasis in animals. The adverse skeletal effects have cast shadows over the promise of FGF21 as a potential therapeutic for obesity-related disorders [6] .
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To date, there is no information on whether FGF21 relates to bone mass in humans. This is clinically important in light of bone loss induced by high FGF21 states in animals. To investigate this, we determine the interrelationship between circulating FGF21 levels, bone mineral density (BMD), and body composition in healthy men and women.
Materials and methods

Subjects
Study participants consisted of 40 volunteers (16 women) recruited through local advertisement to participate in protocols related to energy expenditure/metabolism at the National Institutes of Health (ClinicalTrials.gov identifier numbers NCT00521729 and NCT01730105). Volunteers with full body compositional assessment and sufficient stored blood samples for FGF21 measurement were included in the study. Energy expenditure results of 12 subjects included in the current study have been published previously [7, 8] . All subjects were healthy and on no medications. Women were studied during the follicular phase of the menstrual cycle, except one female who was postmenopausal. Volunteers were admitted to the Metabolic Clinical Research Unit of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Bethesda, Maryland, for fasting blood sampling and assessment of body composition and BMD. The protocol was approved by the NIDDK-NIAMS institutional review board and informed consent was obtained from all subjects.
BMD and body composition BMD and body composition were measured by dual-energy x-ray absorptiometry (Lunar iDXA; GE Healthcare, Madison, WI). Scan analysis was performed using GE Encore 11.10 software. The following parameters were measured in each volunteer: BMD, bone mineral content (BMC), and bone area of total body, spine, pelvis, legs, and arms; fat mass (FM) and lean body mass (LBM). The coefficient of variation of BMD, FM, and LBM were 0.5, 1.0, and 0.5 %, respectively.
FGF21 measurement
Blood samples were collected in EDTA-coated chilled tubes after an overnight fast, immediately separated, and stored at −80°C for later analyses. Plasma FGF21 concentration was measured by ELISA (BioVendor, Oxford, U.K.) according to the manufacturer's protocol, with intra-assay and inter-assay coefficients of variation of 3.6 and 3.8 %, respectively. No cross-reactivity with other human endocrine FGFs (FGF19 and FGF23) has been observed.
Statistical analysis
Statistical analysis was performed using SPSS 20.0 (SPSS, Inc., Chicago, IL). Data are expressed as mean±standard deviation for normally distributed variables. FGF21 levels were skewed, and were therefore log-transformed to normalize distribution in regression analyses. Median (interquartile range) values of FGF21 are presented in descriptive statistics. Men and women were analyzed separately. Comparisons between results were performed using the un-paired t test and the χ 2 test for continuous and categorical baseline characteristics, respectively. Pearson correlation coefficients were used to examine linear relations between variables. Multivariate linear regression models using analysis of variance were constructed to determine the predictors of BMD; the model included age, ethnicity, body compositional parameters, and log FGF21 levels. Association between FGF21 and BMD was further examined by partial correlation analyses controlled for body compositional parameters. An α error of 0.05 was considered the threshold for statistical significance.
Results
Sex-specific cohort characteristics of participating volunteers are shown in Table 1 . As expected, men had significantly higher 
FGF21 and body composition
In men, there was no association between FGF21 concentrations, LBM, FM, or percent body fat. In women, FGF21 levels correlated positively with FM (p<0.01) and percent body fat (p<0.01). There was no relationship between FGF21 and LBM in women.
FGF21 and BMD In a forward step-wise multiple regression analysis controlling for age, ethnicity, height, body weight, body mass index, LBM, FM, and percent body fat, FGF21 was the single independent predictor of total BMD (β=0.47, p=0.003) and spine BMD (β=0.58, p=0.001) in women. The positive relationship between FGF21, total BMD, and spine BMD observed in women remained significant in partial correlation analyses adjusting for body compositional parameters [ESM Supplemental Table 2 ]. Exclusion of the postmenopausal subject did not alter conclusions of study analyses. There was no evidence of significant collinearity; the variance inflation factors for all models were between 1.1 and 1.9.
Discussion
To the best of our knowledge, this is the first study investigating the relationship between FGF21 levels and BMD in humans. We revealed a robust, positive correlation between plasma FGF21 concentrations with BMD in women but not men, independent of age, ethnicity, FM, and LBM. These findings provide a human perspective on FGF21-bone interaction, contrasting with the recently reported bone loss phenotype in various high FGF21 states in rodents [5, 9] . The bone-adipose axis is emerging as a novel endocrine domain critical in reciprocal regulation of energy and skeletal homeostasis [10] . This is exemplified by FGF21, a factor that induces far-reaching effects in bone and adipose tissue. FGF21 augments substrate utilization via PPARα-and PPARγ-dependent pathways in liver and adipose, respectively [2] . High FGF21 states in animals enhance insulin sensitivity and protection against obesity [1] . This is at the expense of severe bone loss secondary to PPARγ-induced osteoblastogenesis inhibition and increased bone resorption [5] . Contrary to a predicted negative association between FGF21 and BMD based on animal findings, we observed a robust positive relationship between FGF21 and BMD at multiple sites in women. Positive correlations were present in men between FGF21 and all BMD sites, but did not reach statistical significance (Fig. 1) .
Our results shed novel insight on FGF21-bone interaction in the context of known animal biology. Bone loss occurs in animals following pharmacological FGF21 administration or overexpression, while the current study indicates a positive association between FGF21 and BMD in human under physiologic conditions. It is possible the effects of FGF21 on skeleton metabolism are dependent on circulating concentration and therefore tissue exposure. We hereof attempt to decipher potential underlying mechanisms based on our findings.
A significant positive correlation between FGF21 and BMD was observed only in women. Such gender dimorphism is reminiscent of our recently reported female-specific association between higher brown adipose tissue (BAT) mass and BMD [11] . Because BAT secretes FGF21 [12] and women have more BAT than men [13] , it is possible that BAT-secreted FGF21 mechanistically links higher FGF21 levels and greater BAT mass with higher BMD. Furthermore, both FGF21 and BAT mass [11] were more strongly associated with spine than total and other regional BMDs; this finding is supportive of region-specific interactions. As vertebral bone marrow fat harbors brown adipocyte-like cells [14, 15] , it is biologically plausible that local BAT-derived FGF21 contributes to the stronger FGF21-BMD association observed at the spine than at other cortical bone sites.
Taken together, we hypothesize bone-adipose paracrine interaction to be the principal mechanism that underlies the positive association between FGF21 and BMD in physiologic states. This is supported by recent in vitro studies revealing an enhancing effect of FGF21 on the osteogenic activity of bone morphogenic protein 2 [16] , a factor also known to stimulate brown adipogenesis [17] . In contrast, bone loss arising from systemic FGF21 administration could be a consequence of the activation of catabolic endocrine bone remodeling pathways by supraphysiologic FGF21 concentrations. Future studies should incorporate bone turnover marker measurements and BAT quantification to further the understanding on the interaction between FGF21, BAT, and bone. This may uncover adipose-bone crosstalk mechanisms directly relevant to humans, given the recent rediscovery of significant BAT depots in adults [18] and the identification of FGF21 as a human brown adipokine [8, 19] .
Small sample size and cross-sectional design are limitations of the current study. Despite careful adjustment for potential confounders, larger confirmatory studies are required to exclude a type 1 error in the observed relationship between FGF21 and BMD, and to assess if this relationship is maintained in elderly individuals. While a type 2 error could explain the absence of these relationships in men, it is also possible that higher LBM in men overshadows the significance of fat-derived FGF21 on bone. We emphasize that a causal relationship between FGF21 and higher BMD cannot be established in the current study. However, our study provides the first human perspective on FGF21 bone biology, which is clinically relevant at a time when FGF21 therapeutic trials are poised to begin. The sequelae of FGF21 treatment in humans on bone and adipose may be more complex than what animal studies have suggested and could ultimately depend on dosing, as well as the balance of its paracrine/endocrine actions and individual BAT abundance.
In summary, the current study reveals a strong positive association between plasma FGF21 levels and BMD in healthy women, independent of age, ethnicity, and other body compositional parameters. No significant correlations were present in men. These findings indicate the recently reported association between bone loss and high FGF21 states in animals may not be directly translated to humans in physiologic states.
